Propranolol: A Promising Therapeutic Avenue for Classic Kaposi Sarcoma
Keywords:
haemangioma, Kaposi Sarcoma, propranolol, LymphedemaAbstract
Introduction: Kaposi sarcoma (KS) is a low grade angio-proliferative tumor of endothelial origin. Human herpes virus 8 (HHV8) plays a major role in the pathogenesis of KS. Classic Kaposi sarcoma is commonly seen among elderly of Mediterranean origin. It is usually slowly progressive and is rarely fatal. There is no definitive cure for KS. Beta blockers were used with great success in the treatment of infantile hemangioma. Because of some similarity between infantile hemangioma and Kaposi sarcoma, topical beta blockers were tried with variable success rate.
Objectives: We aimed to assess the efficacy and safety of oral propranolol in the treatment of classic Kaposi sarcoma.
Methods: Fifteen patients diagnosed with classic Kaposi sarcoma were prospectively enrolled in the study. Detailed history and full clinical examination were conducted. Histopathological diagnosis with confirmatory immune staining was done for all patients. Oral propranolol in a dose of 60 mg was given per day for 6 months. The patients assessed clinically as complete responders, partial responders, and non-responders.
Results: Nine patients (60%) were partial responders; showed 50% reduction in the number of the existing lesions, and 6 patients (40%) were considered non-responders; 3 with stable disease and 3 with progressive disease. Lymphedema partially improved in 1 patient.
Conclusions: Oral propranolol is a safe and good option for treatment of patients with non-complicated classic Kaposi sarcoma, especially elderly with multiple comorbidities.
References
Ruocco E, Ruocco V, Tornesello ML, Gambardella A, Wolf R, Buonaguro FM. Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):413-422. DOI: 10.1016/j.clindermatol.2013.01.008. PMID: 23806158. PMCID: PMC7173141.
Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: A continuing conundrum. J Am Acad Dermatol. 2008;59(2):179-206. DOI:10.1016/j.jaad.2008.05.001. PMID: 18638627.
Liu Z, Fang Q, Zuo J, Minhas V, Wood C, Zhang T. The world‐wide incidence of Kaposi's sarcoma in the HIV/AIDS era. HIV medicine. 2018 May;19(5):355-364. DOI: 10.1111/hiv.12584
Püttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016; 138 (3): e20160355 DOI: 10.1542/peds.2016-0355
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015; 372 (8):735-746 DOI: 10.1056/NEJMoa1404710
Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163 (2): 269–274 DOI: 10.1111/j.1365-2133.2010.09848.
Cuesta AM, Gallardo-Vara E, Casado-Vela J, Recio-Poveda L, Botella LM, Albiñana V. The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases. Int J Mol sci. 2022; 23 (8): 4217. DOI: 10.3390/ijms23084217
Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE. β-adrenergic receptor expression in vascular tumors. Mod Pathol. 2012;25 (11):1446-1451. DOI:10.1038/modpathol.2012.108
Meseguer-Yebra C, Cardenoso-Alvarez ME, Bordel-Gomez MT, Fraile-Alonso MC, Perez-Losada ME, Sanchez-Estella J: Successful treatment of classic Kaposi sarcoma with topical timolol: report of two cases. Br J Dermatol. 2015;173 (3):860-862. DOI: 10.1111/bjd.13746
Alcantara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Velez Garcia-Nieto A: Classic Kaposi's sarcoma treated with topical 0.5% timolol gel. Dermatol Ther. 2016; 29:309-311.
Cmr G, Licata G, Briatico G, et al. Comparison between propranolol 2% cream versus timolol 0.5% gel for the treatment of Kaposi sarcoma. Int J Dermatol. 2021; 60: 631–633. DOI: 10.1111/ijd.15407
Sharquie KE, Noaimi AA. Treatment of Kaposi’s Sarcoma by Combination of Zinc Sulfate and Propranolol. Journal of Cosmetics, Dermatological Sciences and Applications. 2018; 8 (4):249-255. DOI: 10.4236/jcdsa.2018.84026.
Salido-Vallejo R, González-Menchen A, Alcántara-Reifs C, España A. Treatment with Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma. JAMA dermatology. 2022; 11 (7): 832-834. DOI:10.1001/jamadermatol.2022.1278
Mine T, Koike Y, Ehara D, Murota H. A case of bilateral plantar pseudo-Kaposi sarcoma successfully treated with propranolol. JAAD Case Reports. 2021; 18:74-78. DOI: 10.1016/j.jdcr.2021.09.032
Horst C, Kapur N. Propranolol: a novel treatment for angiolymphoid hyperplasia with eosinophilia. Clin Exp Dermatol. 2014; 39 (7): 810-812. DOI:10.1111/ced.12412
Krown SE, Metroka C, Wernz JC. Kaposi sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group oncology committee. J Clin Oncol. 1989; 7 (9):1201–1207
Ramaswami R, Polizzotto MN, Lurain K, et al. Safety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection. Clinical Cancer Research. 2022; 28 (5): 840-850. DOI: 10.1158/1078-0432.CCR-21-3364
Paksoy N, Khanmammadov N, Doğan İ, ,et al. Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study. Medicine. 2023; 102 (5):e32866. DOI: 10.1097/MD.0000000000032866
Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi’s sarcoma: a useful tool for therapeutic choices. Euro J Dermatol. 2003; 28 (1):83-86.
Greene AK, Goss JA. Diagnosis and staging of lymphedema. Semin Plast Surg 2018; 32 (1): 012-016. DOI: 10.1055/s-0038-1635117
Benajiba L, Lambert J, La Selva R, et al. Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study. Cancers. 2021; 13 (11):2519. DOI: 10.3390/cancers13112519
Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol. 2013; 68 (2):313-331. DOI:10.1016/j.jaad.2012.04.018
Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul pharmacol. 2010; 53 (5-6):200-208. DOI:10.1016/j.vph.2010.08.002
Stiles JM, Amaya C, Rains S, et al. Targeting of beta-adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PloS one. 2013;8 (3): e60021. DOI: 10.1371/journal.pone.0060021
Gramolelli S, Schulz TF. The role of Kaposi sarcoma‐associated herpesvirus in the pathogenesis of Kaposi sarcoma. J pathol. 2015; 235 (2):368-380. DOI: 10.1002/path.4441
Chang M, Brown HJ, Collado-Hidalgo A, et al. β-Adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. J virol. 2005; 79 (21):13538-13547. DOI:10.1128/JVI.79.21.13538–13547.2005
McAllister SC, Hanson RS, Manion RD. Propranolol decreases proliferation of endothelial cells transformed by Kaposi's sarcoma-associated herpesvirus and induces lytic viral gene expression. J virol. 2015; 89 (21):11144-11149. DOI: 10.1128/jvi.01569-15
Amaya CN, Perkins M, Belmont A, et al. Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free-and overall-survival in patients diagnosed with metastatic angiosarcoma. Oncoscience. 2018; 5 (3-4):109-119. DOI: 10.18632/oncoscience.413
Santos M, Vilasboas V, Mendes L, Talhari C, Talhari S. Lymphangiectatic Kaposi's sarcoma in a patient with AIDS. An Bras Dermatol. 2013; 88 (2):276-278. DOI 10.1590/S0365-05962013000200019
Brambilla L, Tourlaki A, Ferrucci S, Brambati M, Boneschi V. Treatment of classic Kaposi's sarcoma‐associated lymphedema with elastic stockings. J dermatol. 2006; 33 (7):451-456. DOI: 10.1111/j.1346-8138.2006.00108.x
Montero Pérez I, Rodríguez‐Pazos L, Álvarez‐Pérez A, et al. Kaposi sarcoma following postmastectomy lymphedema. J Cut Pathol. 2015; 42 (11):889-893. DOI: 10.1111/cup. 12573
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rasha Mahmoud Genedy, Marwa Owais, Naglaa Mohamed El Sayed

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.